Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies

Blood

Volumn 87, Issue 12, 1996, Pages 4949-4958

  Hangaishi, Akira ^b   Ogawa, Seishi ^b   Imamura, Nobutaka ^b   Miyawaki, Shuichi ^b   Miura, Yasusada ^b   Uike, Naokuni ^b   Shimazaki, Chihiro ^b   Emi, Nobuhiko ^b   Takeyama, Kunihiko ^b   Hirosawa, Shinsaku ^b   Kamada, Nanao ^b   Kobayashi, Yutaka ^b   Takemoto, Yoshinobu ^b   Kitani, Teruo ^b   Toyama, Keisuke ^b   Ohtake, Shigeki ^b   Yazaki, Yoshio ^b   Ueda, Ryuzo ^b   Hirai, Hisamaru ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; PROTEIN KINASE INHIBITOR; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL CYCLE; CHILD; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE DISRUPTION; GENE LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CARRIER PROTEINS; CELL CYCLE; CELL CYCLE PROTEINS; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION, LEUKEMIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, RETINOBLASTOMA; GENES, TUMOR SUPPRESSOR; HUMANS; INFANT, NEWBORN; LEUKEMIA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0030001435     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.12.4949.bloodjournal87124949     Document Type: Article

References (57)

1. Morgan DO: Principles of CDK regulation. Nature 374:131, 1995
2. Sherr CJ: G1 phase progression: Cycling on cue. Cell 79:551, 1994
3. Hunter T, Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79:573, 1994
4. Hartwell LH, Kastan MB: Cell cycle control and cancer. Science 266:1821, 1994
5. Kamb A: Cell-cycle regulators and cancer. Trends Genet 11:136, 1995
6. Hirama T, Koeffler HP: Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86:841, 1995
7. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7:331, 1993
8. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805, 1993
9. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366:701, 1993
10. el DW, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817, 1993
11. Gu Y, Turck CW, Morgan DO: Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366:707, 1993
12. Noda A, Ning Y, Venable SF, Pereira SO, Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211:90, 1994
13. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67, 1994
14. Polyak K, Lee MH, Erdjument BH, Koff A, Roberts JM, Tempst P, Massague J: Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59, 1994
15. Lee MH, Reynisdottir I, Massague J: Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9:639, 1995
16. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ: p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650, 1995
17. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704, 1993
18. Hannon GJ, Beach D: p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371:257, 1994
19. Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG, Xiong Y: Growth suppression by p18, a p16INK4/ MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8:2939, 1994
20. Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ: Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 15:2672, 1995
21. Chan FK, Zhang J, Cheng L, Shapiro DN, Winoto A: Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. Mol Cell Biol 15:2682, 1995
22. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149, 1995
23. Marx J: How p53 suppresses cell growth. Science 262:1644, 1993
24. el DW, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169, 1994
25. Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B, Koeffler HP: Absence of WAF1 mutations in a variety of human malignancies. Blood 84:3781, 1994
26. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilcyznski S, Lee YY, Bartram CR, Koeffler HP: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 55:2266, 1995
27. Weinberg RA: Tumor suppressor genes. Science 254:1138, 1991
28. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453, 1991
29. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81:323, 1995
30. Kamb A, Gruis NA, Weaver FJ, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436, 1994
31. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753, 1994
32. Kamb A, Shattuck ED, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver FJ, McMlure M, Aitken JF, Anderson DE, Bergman W, Frant R, Goldbar DE, Green A, MacJennan R, Martin NG, Meyer U, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:23, 1994
33. Okamoto A, Demetrick D, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH, Harris CC: Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 91:11045, 1994
34. Aagaard L, Lukas J, Bartkova J, Kjerulff AA, Strauss M, Bartek J: Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines. Int J Cancer 61:115, 1995
35. Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O, Reznikoff C: Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res 55:493, 1995
36. Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, Rollins BJ: Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 55:505, 1995
37. Parry D, Bates S, Mann DJ, Peters G: Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J 14:503, 1995
38. Ogawa S, Hangaishi A, Miyawaki S, Hirosawa S, Miura Y, Takeyama K, Kamada N, Ohtake S, Uike N, Shimazaki C, Toyama K, Hirano M, Mizoguchi H, Kobayashi Y, Furusawa S, Saito M, Emi N, Yazaki Y, Ueda R, Hirai H: Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 86:1548, 1995
39. Ogawa S, Hirano N, Sato N, Takahashi T, Hangaishi A, Tanaka K, Kurokawa M, Tanaka T, Mitani K, Yazaki Y, Hirai H: Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood 84:2431, 1994
40. Furukawa Y, DeCaprio JA, Belvin M, Griffin JD: Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells. Oncogene 6:1343, 1991
41. Cheng J SP Shew JY, Lee WH, Vila V, Haas M: Homozygous deletion of the retinoblastoma gene in an acute lymphoblastic leukemia (T) cell line. Blood 75:730, 1990
42. Imamura J, Miyoshi I, Koeffler HP: p53 in hematologic malignancies. Blood 84:2412, 1994
43. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hosteller R, Cleary K, Bingner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705, 1989
44. Murakami Y, Hayashi K, Hirohashi S, Sekiya T: Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 51:5520, 1991
45. Cheng J, Haas M: Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 10:5502, 1990
46. Murakami Y, Hayashi K, Sekiya T: Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis. Cancer Res 51:3356, 1991
47. Ginsberg AM, Raffeld M, Cossman J: Inactivation of the retinoblastoma gene in human lymphoid neoplasms. Blood 77:833, 1991
48. Prokocimer M, Rotter V: Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematologic cell lineages. Blood 84:2391, 1994
49. Ahuja HG, Jat PS, Foti A, Bar EM, Cline MJ: Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. Blood 78:3259, 1991
50. Igaki H, Sasaki H, Kishi T, Sakamoto H, Tachimori Y, Kato H, Watanabe H, Sugimura T, Terada M: Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines. Biochem Biophys Res Commun 203:1090, 1994
51. Gruis NA, Weaver FJ, Liu Q, Frye C, Eeles R, Orlow I, Lacombe L, Ponce CV, Lianes P, Latres E, Skolnick M, Cordon-Cardo C, Kamb A: Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 146:1199, 1995
52. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27, 1994
53. Stratton MR, Moss S, Warren W, Patterson H, Clark J, Fisher C, Fletcher CD, Ball A, Thomas M, Gusterson BA, Cooper CS: Mutation of the p53 gene in human soft tissue sarcomas: Association with abnormalities of the RB1 gene. Oncogene 5:1297, 1990
54. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T: Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 7:480, 1994
55. Marx J: New link found between p53 and DNA repair. Science 266:1321, 1994
56. Koh J, Enders GH, Dynlacht BD, Harlow E: Tumor-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375:506, 1995
57. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J: Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 375:503, 1995